Rocket Doctor AI Stock Price, News & Analysis

Rocket Doctor AI Inc. (AIRDF) is a healthcare technology company that focuses on artificial intelligence and digital health. According to company disclosures, Rocket Doctor AI delivers physician-built, AI-powered solutions designed to make high-quality healthcare accessible throughout the entire patient journey. The company’s shares trade over-the-counter under the symbol AIRDF and on the Canadian Securities Exchange under the symbol AIDR.

A cornerstone of Rocket Doctor AI’s proprietary technology is the Global Library of Medicine (GLM), which the company describes as a clinically validated decision support system developed with input from hundreds of physicians worldwide. The GLM underpins solutions that provide clinical decision support for healthcare professionals and is positioned as a core asset in the company’s product portfolio. The company states that it has invested years of development into the GLM, focusing on curated, verified medical knowledge and traceable, evidence-based insights.

Business model and digital health platform

Rocket Doctor AI operates at the intersection of artificial intelligence and digital health through its wholly owned subsidiaries, including Rocket Doctor Inc. and Rocket Doctor, Inc. (Rocket Doctor USA). The company indicates that it focuses on a business-to-business model, working with healthcare systems, academic institutions, enterprise partners, and payers. Its digital health platform and marketplace are designed to empower physicians to independently launch and manage their own virtual or hybrid in-person practices.

Company materials state that Rocket Doctor Inc. has helped empower over 300 medical doctors to provide care across more than 700,000 patient visits. The platform and related software systems are described as enabling doctors to manage virtual care, streamline workflows, and reduce the cost of care delivery. By reducing administrative burdens and promoting greater consistency in care, the company reports that its technology is intended to create more time for meaningful physician-patient interactions.

Clinical decision support and AI capabilities

Rocket Doctor AI highlights its AI-powered Clinical Decision Support System (CDSS), built on the Global Library of Medicine. In a partnership with the CAN Health Network and Health Cities in Alberta, the company has described a three-phase rollout that includes AI-powered patient intake via a website-embedded chatbot, real-time clinician support during visits, and integration with electronic medical records. The GLM is described as assisting providers with triage, differential diagnosis, and evidence-based care planning.

The company also notes that it is advancing an AI Nurse platform that utilizes Google Gemini models for conversational AI. Rocket Doctor AI reports that both its GLM and its digital health platform and marketplace are built on Google Cloud, and that it is exploring expanded opportunities as new AI model capabilities become available. The company emphasizes that its GLM is designed to augment clinicians by mitigating the risk of clinical “hallucinations” and supporting traceable, evidence-based recommendations.

Key digital health products and tools

Rocket Doctor AI describes several digital health tools associated with its Rocket Doctor Inc. platform:

• Starship EMR: A digital health platform and electronic medical record system with provider and patient portals. The provider portal is described as supporting tasks such as creating and faxing prescriptions, generating lab and imaging requisitions, conducting patient consultations via video, audio or chat, handling paperwork required in medical practice, and maintaining a complete medical records documentation system. The patient portal allows patients to view appointment history, request new appointments, access medical records such as lab and imaging requisitions and discharge summaries, and update personal profiles.
• RD Connect: A proprietary virtual triage solution that the company reports is in pilot testing with a provincial health network in Canada. RD Connect is described as a virtual agent that automatically triages over 20 unique chief complaints, determining their suitability for virtual care. It uses proprietary triage algorithms and large language models to engage patients with questions in a human-like tone, with the goal of streamlining the care experience and reducing costs.
• RD Health Voyager: A tool in development that leverages large language models to synthesize patient histories by creating summaries of a patient’s medical history. Company materials state that it compiles data from interactions with providers, consultation notes, lab and imaging reports, and intake forms to make it easier for doctors to review key information.

Focus on access to care and target markets

Rocket Doctor AI states that it is committed to reaching underserved, rural, and remote communities in Canada that often lack access to family doctors. The company also highlights support for patients on Medicaid and Medicare in the United States through its Rocket Doctor Inc. platform and payer relationships. Company disclosures describe in-network contracts and credentialing with several major U.S. insurance companies across Medicare Advantage, Veterans Affairs, commercial plans, and Medicaid managed care in states such as New York, California, and Maryland.

The company has also reported initiatives such as pharmacy-based virtual care programs in Canada, emergency department diversion programs using smart triage and AI-enabled care, and partnerships with municipalities to expand access to virtual healthcare services. These activities are presented as examples of how the company’s technology and platform can be applied to improve access and manage healthcare system pressures.

Education and partnerships

Rocket Doctor AI notes that its technology supports educational tools for medical schools. A strategic partnership with Toronto Metropolitan University’s medical school has been announced through its Rocket Doctor Inc. subsidiary. Under this collaboration, independent physicians on the Rocket Doctor platform are connected with clinical education opportunities, facilitating learner observation and mentorship across virtual and other care settings. The company presents this as part of its role in strengthening clinical teaching capacity and preparing future physicians to work in technology-enabled environments.

The company has also referenced a U.S.-based subsidiary, Treatment.com Inc. (Treatment USA), which, in collaboration with Rush River Research, has been awarded an NIH Small Business Innovation Research grant from the National Institute on Minority Health and Health Disparities. According to company communications, this project is intended to further develop and integrate approaches that enhance the handling of medical history data across several commercial platforms.

Strategic transactions and growth initiatives

Rocket Doctor AI has reported that it acquired Rocket Doctor Inc. in 2025, which it states significantly expanded its operating footprint and revenue pipeline. The company has also announced a definitive agreement to acquire Alea Health Holdings Ltd., an online therapy platform that uses conversational AI and voice technology for mental health support. According to the company, Alea’s technology includes a 24/7 AI-powered mental health coach and is expected to enhance Rocket Doctor AI’s capabilities in mental health, particularly through integration with the GLM.

In connection with the Alea transaction, Rocket Doctor AI has stated that Alea’s presence and opportunities in the United Arab Emirates provide an entry point into the Gulf Cooperation Council region. The company characterizes this as a potential extension of its geographic reach and as aligned with its goal of integrating mental health services with primary care through digital and AI-driven tools.

Corporate structure and capital markets

Rocket Doctor AI describes itself as operating through a group of subsidiaries, including Treatment.com Inc., Rocket Doctor Inc., and Rocket Doctor, Inc. (USA). The company has highlighted its engagement with an independent research firm for analyst coverage and has reported private placement financings and share-based compensation grants, such as stock options and restricted share units, to executives, directors, employees, and consultants. These activities are presented as part of its capital markets and corporate development strategy.

Across its disclosures, Rocket Doctor AI emphasizes the combination of physician-built AI, clinically validated decision support, and a digital health platform and marketplace. For investors and observers, the AIRDF stock represents exposure to a company that positions itself within AI-driven healthcare, virtual care delivery, and clinical decision support, based on the company’s own descriptions and public communications.